Lidocaine 5%
$67.00 / 30 Patches
$45 Telehealth visit fee required
Is a prescription, medicated patch used for the relief of pain associated with post-herpetic neuralgia (PHN).¹
- A prescription topical patch for localized, non-narcotic pain management.
- Delivers targeted relief by numbing pain signals at the nerve level.
- Apply the prescribed number of patches only once (maximum of three times per day), to intact skin, for up to 12-hours within a 24-hour period.
$67.00 / 30 Patches
$45 Telehealth visit fee required
Please see Full Prescribing Information , for Lidocaine 5% [package insert]. Parsippany, NJ: YARAL Pharma Inc; 2021.
1. Lidocaine Patch 5% [package insert]. Parsippany, NJ: YARAL Pharma Inc; 2021.
1. Lidocaine Patch 5% [package insert]. Parsippany, NJ: YARAL Pharma Inc; 2021.
Understanding Post-Shingles Nerve Pain
Lidocaine Patch 5% is specifically indicated for the relief of pain associated with Post-Herpetic Neuralgia (PHN). This type of pain is characterized by chronic, often severe, burning or stabbing sensations that can persist for months or years after a shingles infection has healed.
How the Local Anesthetic Works
Unlike oral medications that treat pain systemically, Lidocaine Patch 5% is a local anesthetic. It works by penetrating the skin to block sodium channels in the nerve endings, effectively numbing the area and interrupting the transmission of pain signals to the brain.
Simple Application, Focused Duration
This medicated patch delivers the active ingredient through a simple adhesive system. For effective relief, the patch is applied only to intact skin and is worn for up to 12 continuous hours in a 24-hour period, providing targeted relief where you need it most.
USE & IMPORTANT SAFETY INFORMATION
INDICATION
Lidocaine patch 5% is indicated for relief of pain associated with post-herpetic neuralgia. It should be applied only to intact skin.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Lidocaine patch 5% is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.
WARNINGS
Risk of Methemoglobinemia - Cases of methemoglobinemia have been reported in association with local anesthetic use. All patients are at risk for methemoglobinemia.
- If local anesthetics must be used in patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites, close monitoring for symptoms and signs of methemoglobinemia is recommended as these patients are more susceptible to developing clinical manifestations of the condition.
- Signs of methemoglobinemia, including cyanotic skin discoloration and/or abnormal coloration of the blood may occur immediately or may be delayed some hours after exposure. Methemoglobin levels may continue to rise which may lead to more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue lidocaine patch 5% and any other oxidizing agents. Depending on the severity of the symptoms, patients may respond to supportive care or may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.
Accidental Exposure in Children - Small children or pets could suffer serious adverse effects from chewing or ingesting a new or used lidocaine patch 5%. Store and dispose of lidocaine patch 5% properly and keep out of reach of children, pets and others.
Excessive Dosing and Overdose - Excessive dosing could result in increased absorption of lidocaine and high blood concentrations, leading to serious adverse effects, including lidocaine toxicity. Longer duration of application, application of more than the recommended number of patches, smaller patients, or impaired elimination may all contribute to increased blood concentration levels of lidocaine.
- Apply the prescribed number of patches (maximum of 3), only once for up to 12 hours within a 24-hour period. If lidocaine overdose is suspected, check blood concentration. Management of overdose includes close monitoring, supportive care, and symptomatic treatment.
PRECAUTIONS
- Hepatic Disease: Patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of lidocaine.
- Allergic Reactions: Lidocaine patch 5% should be used with caution in patients allergic to PABA derivatives or with a history of drug sensitivities, especially if the etiologic agent is uncertain.
- Non-Intact Skin: Apply lidocaine patch 5% on intact skin only. Application to broken or inflamed skin may result in higher blood concentrations of lidocaine from increased absorption.
- External Heat Sources: Placement of external heat sources, such as heating pads or electric blankets, over lidocaine patch 5% is not recommended and may increase plasma lidocaine levels.
- Eye Exposure: Avoid contact of lidocaine patch 5% with eyes. If eye contact occurs, immediately wash out the eye with water or saline and protect the eye until sensation returns.
ADVERSE REACTIONS
- Application Site Reactions: Side effects of lidocaine patch 5% include application site reactions such as blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechia, pruritus, vesicles, or may be the locus of abnormal sensation. These reactions are generally mild and transient, resolving spontaneously within a few minutes to hours.
- Allergic Reactions: Allergic and anaphylactoid reactions associated with lidocaine, such as angioedema, bronchospasm, dermatitis, dyspnea, hypersensitivity, laryngospasm, pruritus, shock, and urticaria, can occur and should be managed by conventional means.
- Systemic Reactions: Systemic adverse reactions following appropriate use of lidocaine patch 5% are unlikely and are similar in nature to those observed with other amide local anesthetic agents.
DRUG INTERACTIONS
- Antiarrhythmic Drugs: Lidocaine patch 5% should be used with caution with Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic.
- Local Anesthetics: When lidocaine patch 5% is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.
- Drugs that May Cause Methemoglobinemia When Used with Lidocaine Patch 5%: Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates/nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarial, anticonvulsants, acetaminophen and other drugs associated with the risk of methemoglobinemia.
USE IN SPECIFIC POPULATIONS
- Lactation: Use of lidocaine patch 5% during lactation should be used with caution as lidocaine is excreted in breast milk.
- Pregnancy: Lidocaine patch 5% has not been studied in pregnancy or in labor and delivery and therefore should be used only if clearly needed and total doses contributed by all formulations must be considered.
- Pediatrics: Safety and effectiveness in pediatric patients have not been established.
These are not all of the adverse reactions that may occur with use of lidocaine patch 5%.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088, or contact Yaral Pharma Inc. at 1-866-218-9009.
Please see Full Prescribing Information for Lidocaine patch 5%.
For more information: info@yaralpharma.com 1-866-218-9009 • www.yaralpharma.com
YARAL Pharma Inc., 8 Campus Drive, Suite 201A, Parsippany, NJ 07054 © 2026 YARAL Pharma Inc. All rights reserved.
Lidocaine patch 5% is indicated for relief of pain associated with post-herpetic neuralgia. It should be applied only to intact skin.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Lidocaine patch 5% is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.
WARNINGS
Risk of Methemoglobinemia
- Cases of methemoglobinemia have been reported in association with local anesthetic use. All patients are at risk for methemoglobinemia.
- If local anesthetics must be used in patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites, close monitoring for symptoms and signs of methemoglobinemia is recommended as these patients are more susceptible to developing clinical manifestations of the condition.
- Signs of methemoglobinemia, including cyanotic skin discoloration and/or abnormal coloration of the blood may occur immediately or may be delayed some hours after exposure. Methemoglobin levels may continue to rise which may lead to more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue lidocaine patch 5% and any other oxidizing agents. Depending on the severity of the symptoms, patients may respond to supportive care or may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.
- Small children or pets could suffer serious adverse effects from chewing or ingesting a new or used lidocaine patch 5%. Store and dispose of lidocaine patch 5% properly and keep out of reach of children, pets and others.
- Excessive dosing could result in increased absorption of lidocaine and high blood concentrations, leading to serious adverse effects, including lidocaine toxicity. Longer duration of application, application of more than the recommended number of patches, smaller patients, or impaired elimination may all contribute to increased blood concentration levels of lidocaine.
- Apply the prescribed number of patches (maximum of 3), only once for up to 12 hours within a 24-hour period. If lidocaine overdose is suspected, check blood concentration. Management of overdose includes close monitoring, supportive care, and symptomatic treatment.
- Hepatic Disease: Patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of lidocaine.
- Allergic Reactions: Lidocaine patch 5% should be used with caution in patients allergic to PABA derivatives or with a history of drug sensitivities, especially if the etiologic agent is uncertain.
- Non-Intact Skin: Apply lidocaine patch 5% on intact skin only. Application to broken or inflamed skin may result in higher blood concentrations of lidocaine from increased absorption.
- External Heat Sources: Placement of external heat sources, such as heating pads or electric blankets, over lidocaine patch 5% is not recommended and may increase plasma lidocaine levels.
- Eye Exposure: Avoid contact of lidocaine patch 5% with eyes. If eye contact occurs, immediately wash out the eye with water or saline and protect the eye until sensation returns.
- Application Site Reactions: Side effects of lidocaine patch 5% include application site reactions such as blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechia, pruritus, vesicles, or may be the locus of abnormal sensation. These reactions are generally mild and transient, resolving spontaneously within a few minutes to hours.
- Allergic Reactions: Allergic and anaphylactoid reactions associated with lidocaine, such as angioedema, bronchospasm, dermatitis, dyspnea, hypersensitivity, laryngospasm, pruritus, shock, and urticaria, can occur and should be managed by conventional means.
- Systemic Reactions: Systemic adverse reactions following appropriate use of lidocaine patch 5% are unlikely and are similar in nature to those observed with other amide local anesthetic agents.
- Antiarrhythmic Drugs: Lidocaine patch 5% should be used with caution with Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic.
- Local Anesthetics: When lidocaine patch 5% is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.
- Drugs that May Cause Methemoglobinemia When Used with Lidocaine Patch 5%: Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates/nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarial, anticonvulsants, acetaminophen and other drugs associated with the risk of methemoglobinemia.
- Lactation: Use of lidocaine patch 5% during lactation should be used with caution as lidocaine is excreted in breast milk.
- Pregnancy: Lidocaine patch 5% has not been studied in pregnancy or in labor and delivery and therefore should be used only if clearly needed and total doses contributed by all formulations must be considered.
- Pediatrics: Safety and effectiveness in pediatric patients have not been established.
These are not all of the adverse reactions that may occur with use of lidocaine patch 5%.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088, or contact Yaral Pharma Inc. at 1-866-218-9009.
Please see Full Prescribing Information for Lidocaine patch 5%.
For more information: info@yaralpharma.com 1-866-218-9009 • www.yaralpharma.com
YARAL Pharma Inc., 8 Campus Drive, Suite 201A, Parsippany, NJ 07054 © 2026 YARAL Pharma Inc. All rights reserved.